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ABSTRACT 
 
Background 
Patients with HER2-positive early breast cancer (EBC) preferred 
subcutaneous (SC) trastuzumab, delivered via single-use injection device 
(SID), over the intravenous (IV) formulation (Cohort 1 of the PrefHer study: 
NCT01401166). Here we report patient preference, healthcare professional 
satisfaction, and safety data pooled from Cohort 1 and also Cohort 2, where 
SC trastuzumab was delivered via hand-held syringe. 
Patients and Methods 
Patients were randomized to receive 4 adjuvant cycles of 600 mg fixed-dose 
subcutaneous (SC) trastuzumab followed by 4 cycles of standard intravenous 
(IV) trastuzumab, or vice-versa. The primary endpoint was overall preference 
proportions for SC or IV, assessed by patient interviews in the evaluable ITT 
population. 
Results 
A total of 245 patients were randomized to receive SC followed by IV and 243 
received IV followed by SC (evaluable ITT populations: 235 and 232 patients, 
respectively). SC was preferred by 415/467 (88.9%; 95% CI, 85.7–91.6; P 
< .0001; two-sided test against null hypothesis of 65% SC preference); 45/467 
preferred IV (9.6%; 7–13); 7/467 indicated no preference (1.5%; 1–3). 
Clinician-reported adverse events occurred in 292/479 (61.0%) and 245/478 
(51.3%) patients during the pooled SC and IV periods, respectively; 16 
patients (3.3%) in each period experienced grade 3 events; none were grade 
4/5.  
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Conclusion 
PrefHer revealed compelling and consistent patient preferences for SC over 
IV trastuzumab, regardless of SID or hand-held syringe delivery. SC was well 
tolerated and safety was consistent with previous reports, including the 
HannaH study (NCT00950300). No new safety signals were identified 
compared to the known IV profile in EBC. PrefHer and HannaH confirm that 
SC trastuzumab is a validated and preferred option over IV for improving 
patients’ care in HER2-positive breast cancer. 
 
Word Count 
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INTRODUCTION 
Trastuzumab-containing regimens are standard of care for HER2-positive 
early breast cancer (EBC) and metastatic breast cancer (MBC) [1–3]. A 
600 mg fixed-dose manual injection of subcutaneous trastuzumab (Herceptin® 
SC, F. Hoffmann-La Roche Ltd, Basel, Switzerland) given via hand-held 
syringe  is approved by the European Medicines Agency for EBC and MBC as 
an alternative to conventional intravenous (IV) infusion, based on results of 
the phase III HannaH study (NCT00950300) [4, 5]. An SC single-use injection 
device (SID) has comparable pharmacokinetics and safety to the hand-held 
syringe [6]. 
Intuitively, SC trastuzumab should be more convenient for patients as 
administration requires only 2–5 minutes [7]. Objectively, reductions in 
patients’ infusion chair time, healthcare professionals’ time, and other hospital 
resources have been demonstrated [8, 9]. The international, open-label, 
randomized, PrefHer study (NCT01401166) examined patients’ preferences in 
the adjuvant breast cancer setting for IV or SC delivery via two cohorts using 
both methods of SC trastuzumab administration (SID or hand-held syringe) 
[10]. We present additional and final results of patient preferences in the 
overall study population (data pooled from both cohorts). 
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METHODS 
Patients 
Patient eligibility criteria have been described previously [10] and are available 
in the supplementary material, available at Annals of Oncology online. 
 
Study Design 
After surgery and completion of (neo)adjuvant chemotherapy, patients were 
randomized to receive 4 adjuvant cycles of SC trastuzumab (600 mg fixed 
dose injected into the thigh over approximately 5 minutes) every 3 weeks 
followed by 4 cycles of IV (8 mg/kg loading dose if the patient was randomized 
to receive IV trastuzumab first, 6 mg/kg maintenance doses) every 3 weeks or 
vice-versa (the crossover period, which was assessed in this report) as part of 
their standard trastuzumab [10]. Stratification was by de novo and non-de 
novo trastuzumab groups. Patients received SC trastuzumab via the SID in 
Cohort 1 and the hand-held syringe in Cohort 2. Following the crossover 
period patients received IV trastuzumab in Cohort 1 (unless participating in 
SID self-administration) and SC trastuzumab via hand-held syringe in Cohort 
2. The primary endpoint was the proportion of patients indicating an overall 
preference for SC or IV in each cohort, assessed by two study-specific 
telephone patient interviews (PINTs): one before randomization and one after 
the crossover period. PINTs were conducted by experienced telephone 
interviewers and were stringently quality-controlled to ensure impartial 
questioning. The first interview (PINT1) probed factors that could potentially 
influence preferences, such as previous experiences with drug delivery 
methods, needle phobias, and expected preferences for SC or IV 
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trastuzumab. The second interview (PINT2) probed patients’ experiences with 
each administration method on-study, final preference, strength of the 
preference and reasons for it. Factors influencing preference, strength of the 
preference, and reasons for it were exploratory endpoints. Patients in the SID 
cohort with ≥2 cycles remaining after crossover had the option to self-
administer the SID, with their satisfaction assessed by questionnaire after first 
and last self-administrations as an exploratory endpoint. Secondary endpoints 
were safety and tolerability (assessed using standard methods [11–13]), 
event-free survival, immunogenicity (anti-trastuzumab and anti-recombinant 
human hyaluronidase [rHuPH20] antibodies in blood samples, taken at 
baseline and pre-dose cycle 5, i.e. before crossover) in the SID cohort only, 
healthcare professional satisfaction (assessed by responses of gynecologists, 
oncologists, oncology/specialist chemotherapy nurses, other healthcare 
professionals to the questionnaire question “All things considered with which 
method of administration were you most satisfied?” after the crossover 
period), and healthcare professional-perceived time savings with SC 
trastuzumab, also assessed by questionnaire. 
PrefHer was conducted in accordance with Good Clinical Practice guidelines 
and the Declaration of Helsinki. All participating patients provided written 
informed consent. Approval for the protocol was obtained from appropriate 
local and national independent ethics committees. 
 
Statistical Analyses 
Preference for SC was compared in a non-protocol-specified analysis with a 
two-sided test against a null hypothesis value of 65% [10]. Each cohort was 
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powered independently. Factors potentially influencing preference were 
assessed in terms of their effect on the primary endpoint using logistic 
regression (forward selection by stepwise regression with alpha 0.05) in an 
exploratory manner. 
Statistical analyses were performed with SAS (version 9.1.3). 
Adverse event (AE) analyses are descriptive only. 
 
RESULTS 
Patients 
From October 27, 2011 to December 3, 2012, 488 patients were randomized 
(Figure 1). The safety population included 483 patients (five randomized 
patients did not receive study treatment): 243 SC→IV and 240 IV→SC. 
Twenty-four treated patients did not complete all 8 trastuzumab cycles during 
crossover owing to disease recurrence (nine patients), AEs (grade 2 
congestive heart failure [one patient], left ventricular dysfunction [five patients: 
two grade 1, three grade 3], grade 2 arthralgia [one patient], grade 3 
generalized erythema [one patient]), refusal of treatment (three patients), 
withdrawal of consent (two patients), loss to follow-up (one patient), and 
protocol violation (one patient in the hand-held syringe cohort with lung 
metastases was erroneously randomized and was withdrawn after receiving 
one trastuzumab cycle). Of these patients, eight received SC and IV and 
completed the primary endpoint question in PINT2; therefore, they were 
included in the evaluable ITT population. The remaining 16 patients did not 
complete the primary endpoint question; therefore, the evaluable ITT 
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population comprised 467 patients (235 patients SC→IV and 232 IV→SC). No 
data were missing as all evaluable ITT patients completed both PINTs. 
Baseline patient demographics, tumor characteristics, and treatment history 
were balanced between study arms (Table 1). 
 
Patient Preference  
Primary Endpoint 
At PINT2, 88.9% of patients (415/467) preferred SC (95% CI, 85.7–91.6; P < 
0.0001, two-sided test against the null hypothesis of 65% SC preference), 
9.6% (45/467, 95% CI, 7.1–12.7) preferred IV, and 1.5% (7/467, 95% CI, 0.6–
3.1) had no preference (Figure 2). Results were consistent in both study arms: 
SC→IV arm, 89.8% of patients (211/235, 95% CI, 85.2–93.3) preferred SC, 
8.9% (21/235, 95% CI, 5.6–13.3) preferred IV, and 1.3% (3/235, 95% CI, 0.3–
3.7) had no preference; IV→SC arm, 87.9% of patients (204/232, 83.0–91.8) 
preferred SC, 10.3% (24/232, 95% CI, 6.7–15.0) preferred IV, and 1.7% 
(4/232, 95% CI, 0.5–4.4) had no preference. 
 
Exploratory Analysis: Strength of Preferences 
Overall preference for SC was “very strong” in 64.9% of patients (303/467; 
95% CI, 60.4–69.2), “fairly strong” in 17.3% (81/467, 95% CI, 14.0–21.1), and 
“not very strong” in 6.6% (31/467, 95% CI, 4.6–9.3). Overall preference for IV 
was “very strong” in 5.1% of patients (24/467, 95% CI, 3.3–7.6), “fairly strong” 
in 2.1% (10/467, 95% CI, 1.0–3.9), and “not very strong” in 2.4% (11/467, 
95% CI, 1.2–4.2). 
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Exploratory Analysis: Reasons for Patients’ Preferences 
The two main reasons that patients gave for preferring SC were that it saved 
time and that it resulted in less pain/discomfort/side effects (Table 2). Patients 
reported that SC was the least painful method (60.6% [283/467 patients] vs 
17.3% for IV [81/467]; 22.1% [103/467] reported no difference); it also caused 
less bother from bruising (41.1% [192/467] vs 16.1% [75/467]; 42.8% 
[200/467] reported no difference), or from irritation to the injection site (33.0% 
[154/467] vs 14.6% [68/467]; 52.5% [245/467] reported no difference).  
 
Predefined Exploratory Endpoint: Factors Influencing Preference 
There was a high preference by patients for SC trastuzumab regardless of 
whether they had received IV trastuzumab before enrollment (Figure 2). 
Four terms were found to be significant and therefore kept in the final 
stepwise logistic regression model to select factors that potentially influence 
preference (Supplementary Table S1): expected preferences given at PINT1 
(odds ratio [OR] 2.98, 95% CI, 1.51–5.88), weight (OR 0.41, 95% CI, 0.17–
0.97), needle phobia/anxiety (OR 0.31, 95% CI, 0.14–0.68), and IV delivery 
type for prior chemotherapy (OR 2.31, 95% CI, 1.21–4.41). However, these 
results should be interpreted with caution due to the low number of patients 
who expressed a preference for IV or expressed no preference. 
Hypothetical preference from PINT1 was a factor that influenced final 
preferences. Of the patients who expressed a prior preference for SC, 94.0% 
(203/216) expressed a final preference for SC (Table 3). Of the patients who 
expressed a prior preference for IV or expressed no prior preference, 84.5% 
(212/251) expressed a final preference for SC.  
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Preference for SC was 91.5% (95% CI, 87.4–94.6) for patients receiving IV 
trastuzumab by cannula (236/258 patients), 85.8% (95% CI, 80.2–90.3) for 
those with a venous access device (175/204 patients), and 80.0% (95% CI, 
28.4–99.5) for those who received IV trastuzumab by both venous access 
methods (4/5 patients). Patients also preferred SC over IV regardless of their 
country (Supplemental Table S2). 
 
Exploratory Analysis: Hypothetical Preferred Location and Route of 
Trastuzumab Administration 
Overall, 60.4% of patients (282/467, 95% CI, 55.8–64.9) expressed a 
hypothetical preference to receive SC at home (65.7% in the SID cohort 
[155/236, 95% CI, 59.2–71.7] and 55.0% in the hand-held syringe cohort 
[127/231, 95% CI, 48.3–61.5]) when asked during PINT2 (Supplemental Table 
S3). 
 
Secondary Endpoint: Healthcare Professional Satisfaction 
Two hundred thirty-five healthcare professional questionnaires were 
completed. Responses indicated that most respondents were more satisfied 
with SC administration (77.0% [181/235], 95% CI, 71.1–82.2) than with IV 
(3.0% [7/235], 95% CI, 1.2–6.0). The remaining 20.0% [47/235], 95% CI, 
15.1–25.7) indicated no preference for either route.  
 
Secondary Endpoint: AE Profile 
The AE profile obtained during the crossover period at this interim safety 
analysis is shown in Table 4. Differences between rates in the pooled SC and 
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IV periods were driven by grade 1 events occurring more frequently during the 
SC period. Influenza, dermatitis, syncope, hypertension, left ventricular 
dysfunction, and dyspnea were the most common grade 3 AEs (0.4% of 
patients [two] each). No patients had a grade 4 or 5 AE. No serious AEs were 
considered to be related to trastuzumab and each was resolved without 
sequelae. Twenty-four of 483 patients experienced cardiac events, but only 
two instances were recorded as grade 3 (both were left ventricular 
dysfunction). No cardiac events were reported as serious and there was one 
case of congestive heart failure (grade 2; resolved without sequelae). 
 
Secondary Endpoint: Immunogenicity 
In the SC→IV and IV→SC arms, anti-trastuzumab antibody rates were 0% 
(0/114 evaluable patients [any patient with a pre-dose cycle 5 trastuzumab or 
rHuPH20 antibody result regardless of baseline result]) and 3.4% (4/119), 
respectively, and the anti-rHuPH20 antibody rates were 2.6% (3/115) and 
7.6% (9/119), respectively. No association between AEs and the presence of 
anti-trastuzumab or -rHuPH20 antibodies was observed (data not shown). 
 
DISCUSSION 
Final preference results from PrefHer showed that patients strongly preferred 
SC trastuzumab, regardless of SID or hand-held syringe delivery. These data 
provide an impetus for a change in practice regarding trastuzumab 
administration, and patients should be offered the choice of route. Patients 
should be provided with timely, accurate and easily understandable 
information regarding the available routes of administration, and with the 
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evidence base accumulated showing the experiences and preference of 
patients who received both IV and SC. Future trial designs (including in MBC) 
might use the methodology employed in PrefHer, where appropriate, with 
patient preferences and the reasons for them assessed as an essential part of 
the protocol. 
Patients consistently gave “time saving” as their main reason for SC 
preference [10, 14, 15], which was confirmed by quantitative data from a time-
and-motion sub-study [8, 9]. The SID may save patients further time by 
potentially allowing self-administration at home: the location hypothetically 
preferred by almost two-thirds of the patients in the SID cohort. 
SC trastuzumab was well tolerated and no new safety signals were identified 
compared to the known IV profile in EBC. Additional analyses of PrefHer have 
shown that the safety profile combined from both cohorts is not affected by 
switching from SC to IV or vice-versa [16], further supporting a change for 
patients who prefer this method. As with HannaH [17], trastuzumab and 
rHuPH20 anti-drug antibody rates were low and there was no correlation with 
safety; however, results should be interpreted with caution as anti-
trastuzumab antibody rates may have been underestimated due to the 
presence of trastuzumab in the serum affecting detection of anti-trastuzumab 
antibodies in the assay. 
Interpretation of safety analyses should also take into account the limitations 
of having a short period of time during which the events were recorded for this 
analysis (eight 3-weekly cycles). Future analyses will assess data from the 
continuation periods once all patients have completed follow-up. 
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The apparent discrepancy between increased clinician-reported AEs during 
the SC period and patients’ reports of SC producing less pain, bruising, and 
irritation may have resulted from a more conservative approach to reporting 
due to inexperience with the SC formulation [4]. 
Healthcare professionals were more satisfied with SC regardless of 
administration method. The time-and-motion sub-study has shown that 
healthcare professional time and center costs may be substantially reduced 
using the SID or the hand-held syringe [8, 9], and that healthcare 
professional-perceived clinical management and efficiency was increased with 
either SC method, to the benefit of different stakeholders [9, 18]. Combined 
with the totality of the clinical and patient preference data, SC trastuzumab 
has been shown to provide benefits to both patients and healthcare systems. 
In conclusion, PrefHer revealed compelling and consistent patient preference 
for SC trastuzumab, regardless of delivery method (SID or hand-held syringe). 
Healthcare professionals were also more satisfied with SC over IV 
administration and SC was well tolerated. Safety data, including 
immunogenicity, were consistent with previous reports and no new safety 
signals were identified compared to the known IV profile in EBC.  
Based on data from HannaH and PrefHer, SC trastuzumab is the validated 
and preferred option over IV for improving patients’ care in HER2-positive 
breast cancer. 
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KEY MESSAGE 
PrefHer revealed compelling and consistent patient preference for 
subcutaneous (SC) trastuzumab, regardless of delivery by single-use injection 
device or hand-held syringe. SC trastuzumab was well tolerated and safety 
data, including immunogenicity data, were consistent with previous reports. 
No new safety signals were identified compared to the known intravenous 
trastuzumab profile in early breast cancer. 
 
Character count 
398/400 
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TABLES AND FIGURES 
Table 1. Patient Demographics, Tumor Characteristics, and Treatment History 
(Evaluable Intention-to-Treat Population) 
All patients received prior surgery. aThere were 331 patients who were 
younger than 60 years and 136 who were 60 years or older. bPatients with T4 
tumors received (neo)adjuvant chemotherapy and were eligible for the study.  
ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal 
growth factor receptor 2; IV, intravenous; SC, subcutaneous; SD. 
Table 2. Primary Reasons for Patients’ Preferences (Evaluable Intention-to-
Treat Population) 
Responses to the question “What are the two main reasons for your 
preference?” were recorded verbatim by the interviewer. Four experienced 
researchers independently scrutinized the dataset and provided overarching 
themes or core categories for coding. When broad consensus about these 
had been reached, each researcher independently coded every patient’s 
response; the researchers then reconciled codings with each other and 
determined if any thematic categories could reasonably be collapsed together 
or if a new category was required. 
aSome patients gave only one reason or no reason. Percentages were 
calculated on a per-patient basis (N = 467). 
bStatement based on patient preference and not reflective of clinical data. 
IV, intravenous; SC, subcutaneous. 
Table 3. Expected and Actual Preferences (Evaluable Intention-to-Treat 
Population) 
CI, confidence interval; IV, intravenous; SC, subcutaneous. 
Pivot et al.  22 
Table 4. Adverse Event Profile During the Crossover Period (4 Cycles of SC 
Trastuzumab and 4 Cycles of IV Trastuzumab, Safety Population) 
If a patient had multiple events of the same NCI-CTCAE grade or relationship 
category, they were counted only once in that NCI-CTCAE grade or 
relationship category. 
Patients could be counted in both the SC and IV period columns. 
aOne patient had both grade 1 (mild) and grade 2 (moderate) diarrhea and so 
is counted once in each NCI-CTCAE grade and once overall. 
bThree patients had both grade 1 (mild) and grade 2 (moderate) injection site 
reaction and so are counted once in each NCI-CTCAE grade and once overall. 
ICH, International Conference on Harmonisation; IV, intravenous; NCI-CTCAE, 
National Cancer Institute - Common Terminology Criteria for Adverse Events; 
SC, subcutaneous. 
Figure 1. Trial Profile 
aPatient was screened and randomized but was later found to have a left 
ventricular ejection fraction of 53%. No treatment was given on-trial. 
bPatients who received at least one dose of study treatment. 
cPatients who received at least one dose of SC trastuzumab and IV 
trastuzumab and completed PINT1 and the primary endpoint question in 
PINT2. 
ITT, intention-to-treat; IV, intravenous; PINT, Patient Interview; SC, 
subcutaneous.  
Figure 2. Patients’ Preferences (Evaluable Intention-to-Treat Population) 
Responses to the question “All things considered, which method of 
administration did you prefer?” 
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Error bars represent 95% confidence intervals. 
IV, intravenous; SC, subcutaneous. 
 
SUPPLEMENTARY DATA 
Supplementary Table S1. Logistic Regression (Evaluable Intention-to-Treat 
Population) 
Terms not kept in the final logistic regression were: study arm (SC→IV vs IV→
SC), prestudy trastuzumab treatment, country, age (<60 vs 60 years), 
difficulty traveling to chemotherapy appointments (yes vs no), and IV delivery 
type for prior trastuzumab at PINT2. 
CI, confidence interval; IV, intravenous; PINT, Patient interview; SC, 
subcutaneous. 
Supplementary Table S2. Patient Preference by Country (Evaluable 
Intention-to-Treat Population) 
CI, confidence interval; IV, intravenous; SC, subcutaneous. 
Supplementary Table S3. Hypothetical Preferred Location and Route of 
Trastuzumab Administration (Evaluable Intention-to-Treat Population) 
Responses to the question “So if you could choose IV or SC given at: cancer 
center or clinic, your local hospital, your GP or primary care physician’s office, 
or at your home by trained healthcare professionals which would you prefer?” 
GP, general practitioner; IV, intravenous; SC, subcutaneous; SID, single-use 
injection device. 
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APPENDICES 
Patient eligibility criteria 
Sussex Health Outcomes Research & Education in Cancer (SHORE-C)  
PrefHer study team 
PrefHer study investigators 
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TABLES 
Table 1. Patient Demographics, Tumor Characteristics, and Treatment History 
(Evaluable Intention-to-Treat Population) 
 
Arm A 
SC→IV 
n = 235 
Arm B 
IV→SC 
n = 232 
Age, yearsa 
   Median 
 (min–max) 
53.0 
(29–78) 
52.0 
(27–76) 
Weight, kg 
   Median 
  (min–max) 
68.0 
(35.0–120.0) 
66.0 
(41.0–131.8) 
ECOG at screening, n (%)   
 0 194 (82.6) 187 (80.6) 
 1 41 (17.4) 44 (19.0) 
 Not done 0 1 (0.4) 
TNM classification at 
diagnosis, n (%) 
  Primary tumorb   
 T0 2 (0.9) 5 (2.2) 
 T1 109 (46.4) 90 (38.8) 
 T2 97 (41.3) 100 (43.1) 
 T3 13 (5.5) 23 (9.9) 
 T4 9 (3.8) 14 (6.0) 
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 Not assessable 4 (1.7) 0 
 Unknown 1 (0.4) 0 
Lymph node status 
   Negative 119 (50.6) 110 (47.4) 
 Positive 109 (46.4) 118 (50.9) 
 Not assessable 6 (2.6) 4 (1.7) 
 Unknown 1 (0.4) 0 
HER2-positive, n (%) 
   Yes 235 (100) 232 (100) 
 No 0 0 
Trastuzumab prior to 
enrollment, n (%)   
 De novo 47 (20.0) 47 (20.3)  
 Non-de novo 188 (80.0) 185 (79.7) 
Previous treatment, n (%)   
 Chemotherapy 234 (99.6) 232 (100) 
 Radiotherapy 145 (61.7) 141 (60.8) 
 Hormonal therapy 96 (40.9) 95 (40.9) 
 Lapatinib 0 2 (0.9) 
All patients received prior surgery. aThere were 331 patients who were 
younger than 60 years and 136 who were 60 years or older. bPatients with T4 
tumors received (neo)adjuvant chemotherapy and were eligible for the study. 
ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal 
growth factor receptor 2; IV, intravenous; SC, subcutaneous. 
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Table 2. Primary Reasons for Patients’ Preferences (Evaluable Intention-to-
Treat Population) 
Reason category Total, n (%)a Example 
SC preferred, n = 756 reasons given by 415 patients 
Time saving 375 (80.3) 
“It does affect me being there so 
many hours. 
With this it was ‘Hello’ and ‘Bye’ 
without having 
to spend hours with patients” 
Less 
pain/discomfort/side 
effects 
160 (34.3) 
“The SC method was a lot less 
painful to me 
and my bruises faded faster than 
in the case of 
the intravenous method” 
Ease of administration 62 (13.3) 
“Nurses can take care of many 
patients at the 
same time” 
Convenience to 
patient 
57 (12.2) 
“Busy mum with four young 
children – want to 
get on with life” 
Problems with IV 51 (10.9) 
“No veins to be found as my 
veins are 
collapsing” 
Less stress/anxiety 35 (7.5) “IV reminds one of chemo and 
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isn’t very 
pleasant for the head” 
Other 20 (4.3) “Safer – less risk of infections”b 
IV preferred, n = 64 reasons given by 45 patients 
Fewer reactions (less 
pain, bruising, 
irritation, etc.) 
33 (7.1) 
“Irritation due to the SC” 
Other/don’t know 10 (2.1) 
“Had to have the port flushed 
through when attending for SC 
sessions, so would have been 
easier just to use it anyway” 
Psychological 9 (1.9) 
“When you have IV, you arrive, 
settle yourself. You have about 
30 minutes. You can discuss 
with the nurses and other 
patients. It's a feeling of being ‘at 
home’.” 
Perceived efficacy 6 (1.3) 
“I’m not quite convinced that SC 
has the same effect as IV”b 
Environment/staff 5 (1.1) 
“One has to go there anyway 
and one can sit there with other 
women and exchange 
experience” 
Ecological 1 (0.2) “Device is not environmentally 
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considerations sustainable. It is all thrown away 
after use” 
Responses to the question “What are the two main reasons for your 
preference?” were recorded verbatim by the interviewer. Four experienced 
researchers independently scrutinized the dataset and provided overarching 
themes or core categories for coding. When broad consensus about these 
had been reached, each researcher independently coded every patient’s 
response; the researchers then reconciled codings with each other and 
determined if any thematic categories could reasonably be collapsed together 
or if a new category was required. 
aSome patients gave only one reason or no reason. Percentages were 
calculated on a per-patient basis (N = 467). 
bStatement based on patient preference and not reflective of clinical data. 
IV, intravenous; SC, subcutaneous. 
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Table 3. Expected and Actual Preferences (Evaluable Intention-to-Treat Population) 
 PINT1: Preferred method of administration  
 
IV 
 n = 46 
SC 
n = 216 
No preference 
n = 205 
Overall 
N = 467 
PINT2: Preferred method  
of administration, n (%)  
 
IV 11 (23.9) 12 (5.6) 22 (10.7) 45 (9.6%) 
SC 33 (71.7) 203 (94.0) 179 (87.3) 415 (88.9%) 
No preference 2 (4.3) 1 (0.5) 4 (2.0) 7 (1.5%) 
SC preferred  
(exact binomial)  
 
Estimated 
proportion, % 71.7 94.0 87.3 88.9 
95% CI 56.5 to 84.0 89.9 to 96.8 82.0 to 91.5 85.7 to 91.6 
CI, confidence interval; IV, intravenous; PINT, Patient interview; SC, subcutaneous. 
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Table 4. Adverse Event Profile During the Crossover Period (4 Cycles of SC Trastuzumab and 4 Cycles of IV Trastuzumab, Safety 
Population) 
 
SC period 
(all arms pooled) 
n = 479 
IV period 
(all arms pooled) 
n = 478 
Adverse events (all NCI-CTCAE grades), n (%) 292 (61.0) 245 (51.3) 
 Grade 1 (mild) 253 (52.8) 195 (40.8) 
 Grade 2 (moderate) 116 (24.2) 106 (22.2) 
 Grade 3 (severe) 16 (3.3) 16 (3.3) 
 Grade 4 (life-threatening) 0 0 
 Grade 5 (death) 0 0 
Most frequent adverse events (≥5% of patients in the SC, IV, or 
crossover periods, all NCI-CTCAE grades), n (%)   
 Arthralgia 24 (5.0) 27 (5.6) 
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  Grade 1 (mild) 20 (4.2) 22 (4.6) 
  Grade 2 (moderate) 4 (0.8) 5 (1.0) 
  Grade 3 (severe) 0 0 
 Asthenia 27 (5.6) 23 (4.8) 
  Grade 1 (mild) 15 (3.1) 18 (3.8) 
  Grade 2 (moderate) 12 (2.5) 5 (1.0) 
  Grade 3 (severe) 0 0 
 Hot flush 23 (4.8) 16 (3.3) 
  Grade 1 (mild) 16 (3.3) 10 (2.1) 
  Grade 2 (moderate) 7 (1.5) 6 (1.3) 
  Grade 3 (severe) 0 0 
 Fatigue 19 (4.0) 18 (3.8) 
  Grade 1 (mild) 13 (2.7) 12 (2.5) 
  Grade 2 (moderate) 6 (1.3) 6 (1.3) 
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  Grade 3 (severe) 0 1 (0.2) 
 Nausea 25 (5.2) 14 (2.9) 
  Grade 1 (mild) 20 (4.2) 12 (2.5) 
  Grade 2 (moderate) 4 (0.8) 2 (0.4) 
  Grade 3 (severe) 0 0 
  Missing 1 (0.2) 0 
 Headache 20 (4.2) 16 (3.3) 
  Grade 1 (mild) 14 (2.9) 12 (2.5) 
  Grade 2 (moderate) 6 (1.3) 3 (0.6) 
  Grade 3 (severe) 0 1 (0.2) 
 Injection site pain 32 (6.7) 0 
  Grade 1 (mild) 28 (5.8) 0 
  Grade 2 (moderate) 4 (0.8) 0 
  Grade 3 (severe) 0 0 
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 Injection site reaction 30 (6.3)b 0 
  Grade 1 (mild) 29 (6.1) 0 
  Grade 2 (moderate) 4 (0.8) 0 
  Grade 3 (severe) 0 0 
 Injection site erythema 27 (5.6) 0 
  Grade 1 (mild) 24 (5.0) 0 
  Grade 2 (moderate) 3 (0.6) 0 
  Grade 3 (severe) 0 0 
 Diarrhea 16 (3.3)a 12 (2.5) 
  Grade 1 (mild) 12 (2.5) 10 (2.1) 
  Grade 2 (moderate) 5 (1.0) 2 (0.4) 
  Grade 3 (severe) 0 0 
 Pain in extremity 18 (3.8) 7 (1.5) 
  Grade 1 (mild) 17 (3.5) 2 (0.4) 
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  Grade 2 (moderate) 1 (0.2) 5 (1.0) 
  Grade 3 (severe) 0 0 
Cardiac adverse events, n (%) 11 (2.3) 14 (2.9) 
 Ejection fraction decreased (grade 1 [mild]) 4 (0.8) 2 (0.4) 
 Left ventricular dysfunction 2 (0.4) 6 (1.3) 
  Grade 1 (mild) 2 (0.4) 3 (0.6) 
  Grade 2 (moderate) 0 1 (0.2) 
  Grade 3 (severe) 0 2 (0.4) 
 Palpitations (grade 1 [mild]) 3 (0.6) 2 (0.4) 
 Bradycardia 1 (0.2) 3 (0.6) 
  Grade 1 (mild) 1 (0.2) 2 (0.4) 
  Grade 2 (moderate) 0 1 (0.2) 
 Cardiac failure congestive (grade 2 [moderate], resolved 
 without sequelae) 1 (0.2) 0 
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 Extrasystoles (grade 1 [mild]) 1 (0.2) 0 
 Angina pectoris (grade 2 [moderate]) 0 1 (0.2) 
 Heart valve incompetence (grade 1 [mild]) 0 1 (0.2) 
 Mitral valve incompetence (grade 1 [mild]) 0 1 (0.2) 
 Electrocardiogram change (grade 1 [mild]) 0 1 (0.2) 
Serious adverse events (ICH E2A), n (%) 4 (0.8) 4 (0.8) 
 Breast expander infection 1 (0.2) 0 
 Axilla abscess 1 (0.2) 0 
 Benign breast adenoma 1 (0.2) 0 
 Hematoma (not at the injection site) 1 (0.2) 0 
 Wound infection 0 1 (0.2) 
 Influenza 0 1 (0.2) 
 Cholelithiasis 0 1 (0.2) 
 Suture-related complication (post-laparotomy) 0 1 (0.2) 
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 Mental disorder 0 1 (0.2) 
 Related to study treatment 0 0 
 Fully resolved without sequelae 4 (0.8) 4 (0.8) 
Study drug discontinued due to adverse events, n (%) 5 (1.0) 6 (1.3) 
If a patient had multiple events of the same NCI-CTCAE grade or relationship category, they were counted only once in that NCI-
CTCAE grade or relationship category. 
Patients could be counted in both the SC and IV period columns. 
aOne patient had both grade 1 (mild) and grade 2 (moderate) diarrhea and so is counted once in each NCI-CTCAE grade and once 
overall. 
bThree patients had both grade 1 (mild) and grade 2 (moderate) injection site reaction and so are counted once in each NCI-
CTCAE grade and once overall. 
ICH, International Conference on Harmonisation; IV, intravenous; NCI-CTCAE, National Cancer Institute - Common Terminology 
Criteria for Adverse Events; SC, subcutaneous.
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Figure 1. Trial Profile 
 
aPatient was screened and randomized but was later found to have a left ventricular 
ejection fraction of 53%. No treatment was given on-trial. 
bPatients who received at least one dose of study treatment. 
cPatients who received at least one dose of SC trastuzumab and IV trastuzumab and 
completed PINT1 and the primary endpoint question in PINT2. 
ITT, intention-to-treat; IV, intravenous; PINT, Patient Interview; SC, subcutaneous.  
  
Pivot et al.  39 
Figure 2. Patients’ Preferences (Evaluable Intention-to-Treat Population) 
 
Responses to the question “All things considered, which method of administration 
did you prefer?” 
Error bars represent 95% confidence intervals. 
IV, intravenous; SC, subcutaneous. 
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SUPPLEMENTARY DATA 
Supplementary Table S1. Logistic Regression (Evaluable Intention-to-Treat Population) 
Factor Preferred SC in 
PINT2, % 
Odds ratio 95% CI 
Expected preferences given at PINT1    
SC 94.0 
2.98 1.51–5.88 
IV/no  preference 84.5 
Weight    
<80 kg 87.5 
0.41 0.17–0.97 
≥80 kg 92.9 
Needle phobia/anxiety    
Yes 77.6 
0.31 0.14–0.68 
No 90.2 
IV delivery type for prior chemotherapy at PINT1    
 Cannula 93.3 
2.31 1.21–4.41 
 Other in situ venous access devices 84.8 
Terms not kept in the final logistic regression were: study arm (SC→IV vs IV→SC), prestudy trastuzumab treatment, country, age 
(<60 vs 60 years), difficulty traveling to chemotherapy appointments (yes vs no), and IV delivery type for prior trastuzumab at 
PINT2. 
CI, confidence interval; IV, intravenous; PINT, Patient interview; SC, subcutaneous.  
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Supplementary Table S2. Patient Preference by Country (Evaluable Intention-to-Treat Population) 
Preference  
Denmark 
n = 24 
France 
n = 98 
Germany 
n = 78 
Italy 
n = 28 
Russia 
n = 59 
Spain 
n = 83 
 
Sweden 
n = 10 
Switzerland 
n = 8 
Turkey 
n = 10 
United 
Kingdom 
n = 35 
Poland 
n = 17 
Canada 
n = 17 
Preferred 
method, 
n (%)            
IV  1 (4.2) 10 (10.2) 12 (15.4) 2 (7.1) 4 (6.8) 7 (8.4) 1 (10.0) 2 (25.0) 3 (30.0) 3 (8.6) 0 0 
SC  23 (95.8) 85 (86.7) 65 (83.3) 26 (92.9) 55 (93.2) 76 (91.6) 9 (90.0) 6 (75.0) 5 (50.0) 32 (91.4) 17 (100) 16 (94.1) 
No preference  0 3 (3.1) 1 (1.3) 0 0 0 0 0 2 (20.0) 0 0 1 (5.9) 
SC preferred 
(exact 
binomial)            
Estimated 
proportion, %  95.8 86.7 83.3 92.9 93.2 91.6 90.0 75.0 50.0 91.4 100 94.1 
95% CI  78.9–99.9 78.4–92.7 73.2–90.8 76.5–99.1 83.5–98.1 83.4–96.5 55.5–99.7 34.9–96.8 18.7–81.3 76.9–98.2 80.5–100 71.3–99.9 
CI, confidence interval; IV, intravenous; SC, subcutaneous. 
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Supplementary Table S3. Hypothetical Preferred Location and Route of 
Trastuzumab Administration (Evaluable Intention-to-Treat Population) 
Location and route 
SID cohort 
overall, n (%) 
N = 236 
Hand-held 
syringe cohort 
overall, n (%) 
N = 231 
Combined 
overall, n (%) 
N = 467 
IV at cancer center  
or clinic 7 (3.0) 14 (6.1) 21 (4.5) 
SC at cancer center  
or clinic 44 (18.6) 50 (21.6) 94 (20.1) 
IV at local hospital 2 (0.8) 2 (0.9) 4 (0.9) 
SC at local hospital 8 (3.4) 7 (3.0) 15 (3.2) 
IV at GP or primary care 
physician’s office 2 (0.8) 2 (0.9) 4 (0.9) 
SC at GP or primary care 
physician’s office 12 (5.1) 21 (9.1) 33 (7.1) 
IV at home 4 (1.7) 5 (2.2) 9 (1.9) 
SC at home 155 (65.7) 127 (55.0) 282 (60.4) 
Unknown 2 (0.8) 3 (1.3) 5 (1.1) 
Responses to the question “So if you could choose IV or SC given at: cancer center 
or clinic, your local hospital, your GP or primary care physician’s office, or at your 
home by trained healthcare professionals which would you prefer?” 
GP, general practitioner; IV, intravenous; SC, subcutaneous; SID, single-use 
injection device.
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APPENDICES 
Patient eligibility criteria (Pivot X, Pivot X, Gligorov J, Müller V et al. Preference 
for subcutaneous or intravenous administration of trastuzumab in patients 
with HER2-positive early breast cancer (PrefHer): an open-label randomised 
study. Lancet Oncol 2013; 14: 962–970). 
Eligible patients were women aged ≥18 years with HER2-positive 
(immunohistochemistry 3+ or in situ hybridization-positive), histologically confirmed 
primary invasive breast adenocarcinoma, no evidence of residual, locally recurrent, 
or metastatic disease after completion of surgery and chemotherapy (neoadjuvant or 
adjuvant), an Eastern Cooperative Oncology Group performance status of 0 or 1, 
and a baseline left ventricular ejection fraction of ≥55% before the first trastuzumab 
dose. HER2-positivity was assessed by local laboratories with validated assays, 
according to recommendations outlined in the summary of product characteristics for 
IV trastuzumab. Radiotherapy or hormone therapy was allowed. Patients had to 
have been either trastuzumab-naïve (de novo group) or already receiving 
intravenous trastuzumab (non-de novo group) as part of their (neo)adjuvant therapy, 
and they had to have at least 8 out of the total 18 planned 3-weekly trastuzumab 
cycles remaining before enrollment. 
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Sussex Health Outcomes Research & Education in Cancer (SHORE-C)  
PrefHer study team 
Lesley Fallowfield 
Valerie Jenkins 
Justine Kilkerr 
Carolyn Langridge 
Kathryn Monson 
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Ann Knoop Copenhagen University Hospital 
France   
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Mireille Mousseau Hôpital Albert Michallon 
Laurent Zelek Hôpital Avicenne 
Hugues Bourgeois Clinique Victor Hugo 
Claudia Plesse Lefeuvre Centre Eugène Marquis 
Thomas Bachelot Centre Léon Bérard 
Thierry Petit Centre Paul Strauss 
Etienne Brain Centre René Huguenin 
Christelle Levy CRLCC-François Baclesse 
Joseph Gligorov APHP Hôpital Tenon 
Germany   
Doris Augustin Donauisar Klinikum Deggendorf 
Heiko Graf Klinikum Meiningen Klinik für 
Gynäkologie und Geburtshilfe 
Georg Heinrich Schwerpunktpraxis Dr.med. Georg 
Heinrich 
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Hendrik Kroening Onkologische Gemeinschaftspraxis 
Sherko Kuemmel Klinikum Essen-Mitte Ev. Huyssens-
Stiftung / Knappschafts GmbH 
Volkmar Müller University Medical Center Hamburg-
Eppendorf 
Friedrich Overkamp Praxis für Onkologie und Hämatologie 
Tjoung-Won Park-Simon Medizinische Hochschule Hannover, 
Klinik für Frauenheilkunde und 
Geburtshilfe 
Marcus Schmidt Uniklinik Mainz 
Lidia Perlova-Griff Sankt Gertrauden-Krankenhaus 
Brustzentrum 
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Italy   
Marco Colleoni IRCCS Istituto Europeo Di Oncologia 
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Alberto Ballestrero Uni Degli Dtudi Di Genova 
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Raffaele 
Giuseppe Curigliano European Institute of Oncology 
Poland   
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Elzbieta Brewczynska Cent. Onkologii - Instytut im. M. S-
Curie, Klinika Now. Piesi i Chirurgii 
Rekon. 
Jacek Jassem Uniwersyteckie Centrum Kliniczne, 
Klinika Onkologii i Radioterapii 
Russia   
Vadim Shirinkin State Institute Of Healthcare Orenburg 
Regional Clinical Oncology Dispensary 
Alexey Manikhas City Oncology Dispensary 
Victoria Dvornichenko Regional Oncology Hospital 
Mikhail Lichinitser Blokhin Cancer Research Center 
Vladimir Semiglazov NN Petrov Research Institute of 
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Dispensary 
Spain   
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Francisco Carabantes Ocon Hospital Regional Universitario Carlos 
Haya 
Guillermo López Vivanco University Hospital Cruces, San 
Vicente de Barakaldo, Vizcaya 
Javier Salvador Bofill Hospital Universitario Nuestra Señora 
de Valme 
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Luis De La Cruz Merino Hospital Universitario Virgen Macarena 
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Santos Enrech Frances Hospital Universitario de Getafe 
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